21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes

Yiwei Tong, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen & Kunwei Shen

The 21-gene recurrence score (RS) assay is prognostic and predictive for hormone receptor (HR)+/HER2-/node- breast cancer (BC) patients. However, its clinical value in node+ patients hasn’t been elucidated. HR+/HER2-/pN1 patients operated in Comprehensive Breast Health Center, Shanghai Ruijin Hospital from January 2014 to December 2018, with available RS results were retrospectively included. Clinico-pathological characteristics were compared. Adjuvant chemotherapy recommendations pre-/post-RS assay and actual usage were analyzed. A total of 303 patients were included, with 59, 178, 66 RS < 18, 18–30 and ≥ 31. Age (P < 0.001), comorbidity (P = 0.013), and RS category (P < 0.001) were independently associated with chemotherapy recommendation. Compared with low RS patients, those with intermediate (OR 6.58, 95% CI 2.37–18.31, P < 0.001) or high (OR 54.14, 95% CI 3.77–776.54, P = 0.003) RS were more likely to be recommended with chemotherapy. RS independently influence chemotherapy decision in postmenopausal population as well. Chemotherapy recommendation changed for 9.57% patients after RS assay. Patient adherence rate to chemotherapy recommendation was 94.72% (287/303). The 21-gene RS independently influenced chemotherapy recommendation in pN1 BC patients, which could provide additional information to guide chemotherapy decision with relatively good treatment adherence rate.

Breast cancer (BC) is the most common malignant tumor in women worldwide. According to the latest global epidemiological cancer survey, an estimated 2.1 million new BC cases would be diagnosed in 2018, representing 25% of all cancer cases among women. BC is estimated to be responsible for 626,700 deaths, accounting for 6.6% of all cancer deaths. As an essential part of systemic treatment, standard adjuvant chemotherapy reduces one third breast cancer mortality compared with no chemotherapy. Patients with high absolute risk of disease recurrence and death gain most absolute benefit from chemotherapy, independent of classical clinico-pathological characteristics including age, hormone receptor (HR) status or node involvement.

21-gene recurrence score (RS) is the most frequently applied multigene assay in clinical practice to provide individualized information other than routine clinico-pathological features, which can predict chemotherapy benefit and guide adjuvant treatment decision in HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, and node-negative BC patients. The assay is designed to measure the expression of 21 genes including 16 cancer-related genes and 5 endogenous references in formalin-fixed paraffin-embedded (FFPE) breast tumors using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) methods. According to the results of the prospective TAILORx trial, the 2018 NCCN Clinical Practice Guidelines in Oncology for Breast Cancer suggest to spare selective low risk patients from adjuvant chemotherapy. Meanwhile, based on the NSABP B-20 trial, chemotherapy is still recommended for high risk patients, since a 27.6% absolute decrease of 10-year distant recurrence rate was reported in high risk N0 patients receiving chemotherapy.

While the current guidelines suggest the routine use of 21-gene RS testing in node-negative patients, results from several clinical trials have extended its application in patients with 1–3 histologically proven involved axillary lymph nodes (ALNs). Retrospective analysis from phase III SWOG 8814 trial demonstrated that
TC pathologists. The methods and criteria for immunohistochemistry (IHC) assessment of estrogen receptor (ER), and IHC HER2 +/HER2 0, IHC HER2 1+/HER2- defined as ER+ and PR+ defined as ER+ and PR+. Molecular subtype classification was based on 2013 St. Gallen expert panel consensus, with Luminal A-like being defined as ER+/PR ≥ 20%/HER2- and Ki-67 < 14%, while Luminal B-like being defined as ER−/PR−/HER2- or ER+/HER2+/Ki-67 ≥ 14% or ER+/HER2+/Ki-67 ≥ 14% or HER2 amplified. Molecular subtype classification was based on 2013 St. Gallen expert panel consensus, with Luminal A-like being defined as ER+/PR ≥ 20%/HER2- and Ki-67 < 14%, while Luminal B-like being defined as ER−/PR−/HER2- or ER+/HER2+/Ki-67 ≥ 14% or ER+/HER2+/Ki-67 ≥ 14% or HER2 amplified. Histo-pathologic analysis. Tumor histo-pathologic analysis was performed in the Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China by experienced pathologists. The methods and criteria for immunohistochemistry (IHC) assessment of estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 were as described in our previous reports. The cutoff of ER expression was set at 50% because the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 has suggested that tumor cell staining for HR ≥ 50% indicated highly endocrine-responsive tumors. HER2 negativity was identified according to the 2018 ASCO/CAP guidelines, which included IHC HER2 0, IHC HER2 1+, and IHC HER2 2+ with fluorescence in situ hybridization HER2 non-amplified. Molecular subtype classification was based on 2013 St. Gallen expert panel consensus, with Luminal A-like being defined as ER+/PR ≥ 20%/HER2- and Ki-67 < 14%, while Luminal B-like being defined as ER−/PR−/HER2- or ER+/HER2+/Ki-67 ≥ 14% or ER+/HER2+/Ki-67 ≥ 14% or HER2 amplified.

Evaluation of 21-gene RS. The detailed information of 21-gene RS evaluation was described in our previous work. RNA was extracted from three 10-μm unstained sections of FFPE breast tumor tissue, which was prepared by experienced pathologists in the Department of Pathology, using RNeasy FFPE RNA kit (Qiagen, 73504, Germany). Reverse transcription was performed using Omniscript RT kit (Qiagen, 205111, Germany). Quantitative RT-PCR was accomplished using Premix Ex TaqTM (TaKaRa Bio, RR390A) in Applied Biosystems 7500 Real-Time PCR System (Foster City, CA). Gene expression was verified in triplicate, and normalized to five endogenous reference genes. Gene-specific normalized cycle threshold value was applied to calculate RS. For patients with multifocal disease, the highest RS was recorded.

Treatment decision. Treatment choices pre- and post-RS were both decided through a two-round multidisciplinary team (MDT) meeting including surgical oncologists, medical oncologists, radiation oncologists, pathologists, BC specialized nurses, and other related specialists. After the completion of histo-pathologic analysis, a first-round MDT would be held to give an initial recommendation of adjuvant treatment regimen based on patients’ clinicopathological features. For those who need additional information to guide treatment choice, MDT would recommend a 21-gene RS test. After receiving the RS result, a final treatment recommendation would be made through a second-round MDT based on traditional clinicopathological features and RS. Frequently suggested chemotherapy regimen included EC-T, 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² every 21 days followed by 4 cycles of docetaxel 100 mg/m² every 21 days or 12 cycles of weekly paclitaxel 80 mg/m²; TC*4, 4 cycles of docetaxel 75 mg/m² plus cyclophosphamide 600 mg/m² every 21 days; TC*6, 6 cycles of docetaxel 75 mg/m² plus cyclophosphamide 600 mg/m² every 21 days. Actual chemotherapy usage and regimen were confirmed during follow-up, which was accomplished by the BC specialized nurses in our center.

Statistical analysis. The 21-gene RS was calculated from the reference-normalized formula. Since the optimal RS cutoff in node-positive patients remains unknown, here we adopted two classifications. The classic classification divided patients into three risk groups: low RS (RS < 18), intermediate RS (18–30), and high RS (≥31), respectively. Another more specific classification was also presented (RS < 11, 11–17, 18–25, 26–30, and ≥31) based on classic and new TAILORx trial category classifications. Charlson Comorbidity Index was applied to evaluate patient comorbidity. Categorical variables were analyzed by using Chi-square test or Fisher’s exact test. Multivariate logistic regression was used to identify the impact factors for treatment recommendation. The change of treatment recommendation before and after 21-gene RS result was calculated by the subtraction between pre- and post-RS chemotherapy recommendation. Disease-free survival (DFS) was calculated from definitive surgery to the first proven local regional recurrence, distant metastasis, contralateral BC, second malignancy or death of any cause. Kaplan-Meier curve was applied to compare DFS between RS groups. Data were analyzed using IBM SPSS statistics software version 23 (SPSS, Inc., Chicago, IL). Two-sided P values < 0.05 were considered statistically significant.
Ethical approval. This study was reviewed and approved by the independent Ethical Committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from each patient.

Results
Baseline characteristics. Overall, 303 women were enrolled in this study (Fig. 1). The baseline characteristics of the participants were presented in Table 1. The mean age was 59.41 ± 12.02 (range 30–89) years. Charlson Comorbidity Index was 0, 1, and ≥ 2 in 184, 81, and 38 patients, respectively. Invasive ductal carcinoma (IDC) was diagnosed in 279 out of 303 patients, while others had invasive lobular carcinoma, mucinous carcinoma, or mixed carcinoma. Grade I-II tumors were found in 73.27% (222/303) patients. There were 19.80%, 52.48%, 22.44%, and 5.28% patients with micro-metastases, one, two, and three positive ALN(s), respectively. All patients had ER-positive disease, of whom only 7 had ER staining in less than 50% BC cells. PR was less than 20% in 81 patients and 19 were PR-negative. One hundred and eighty-nine (62.38%) patients had Ki-67 ≥ 14%. Luminal A-like and Luminal B-like subtypes accounted for 26.07% and 73.39% of the study population.

The number of pN1 patients receiving 21-gene RS was 66/763 (8.65%) before 2015, 53/176 (30.11%) in 2015, and 184/640 (28.75%) in 2016–2018. the application rate of 21-gene RS was 19.84% in pre-/perimenopausal patients, and 42.78% in postmenopausal patients. According to 21-gene RS, 59 (19.47%), 178 (58.75%), and 66 (21.78%) patients were categorized into low, intermediate, and high risk groups, respectively. Univariate (Supplementary Table S1) and multinomial logistic regression showed that the overall distribution of grade ($P = 0.009$), ER status ($P = 0.009$), and PR status ($P < 0.001$) had a significant difference among low, intermediate, and high risk groups (Supplementary Table S2). Those with RS ≥ 31 were less often of grade II tumors compared with intermediate risk patients (odds ratio [OR] 0.39, 95% confidence interval [CI] 0.20–0.75, $P = 0.015$). All 7 patients of ER < 50 were in the high risk group ($P = 0.009$). When compared to the patients with 21-gene RS 18–30, low RS patients were less often PR < 20% (OR 0.12, 95% CI 0.03–0.55, $P = 0.007$) while high risk ones were more possible PR < 20% (OR 2.57, 95% CI 1.27–5.21, $P = 0.009$).

Impact factors for chemotherapy recommendation. The distribution of post-assay chemotherapy recommendation by RS subgroups was shown in Fig. 2. Chemotherapy was recommended in 59.32%, 88.76% and 98.48% of low, intermediate and high risk patients, respectively (Fig. 2A). When further classified by RS, 59.47%, 85.73%, and 93.08% patients were categorized into low, intermediate, and high risk groups, respectively (Fig. 2B). Those with RS ≥ 31 were less often of grade II tumors compared with intermediate risk patients (odds ratio [OR] 0.39, 95% confidence interval [CI] 0.20–0.75, $P = 0.015$). All 7 patients of ER < 50 were in the high risk group ($P = 0.009$). When compared to the patients with 21-gene RS 18–30, low RS patients were less often PR < 20% (OR 0.12, 95% CI 0.03–0.55, $P = 0.007$) while high risk ones were more possible PR < 20% (OR 2.57, 95% CI 1.27–5.21, $P = 0.009$).

Figure 1. Flow chart of included patients. Abbreviations: ALN, axillary lymph node; CBHC, Comprehensive Breast Health Center; HER2, human epidermal growth factor receptor 2.
Compared with patients <50 years old, elder patients >70 years old were less likely to be recommended with chemotherapy (OR 0.01, 95% CI 0.00–0.11, $P = 0.001$). Those with comorbidity score of 2 or more had less possibility of chemotherapy recommendation compared to those without any comorbidity (OR 0.08, 95% CI 0.02–0.46, $P = 0.004$). Patients with intermediate RS (OR 6.58, 95% CI 2.37–18.31, $P < 0.001$) or high RS (OR 54.14, 95% CI 3.77–776.54, $P = 0.003$) were more likely to be recommended to receive chemotherapy than those with low RS.

### Table 1. Baseline characteristics of study participants and impact factors for chemotherapy decision. †Chemo or Non-chemo was judged upon final multidisciplinary recommendation. Abbreviations: ALN, axillary lymph node; BCS, breast conserving surgery; Chemo, chemotherapy; ER, estrogen receptor; IDC, invasive ductal carcinoma; PR, progesterone receptor; RS, recurrence score.

| Characteristics                  | Total N = 303 | Chemo† N = 258 (%) | Non-Chemo† N = 45 (%) | $P$-value |
|----------------------------------|---------------|--------------------|-----------------------|-----------|
| **Age (years)**                 |               |                    |                       | <0.001    |
| <50                              | 68 (22.44)    | 66 (25.58)         | 2 (4.44)              |           |
| 50–70                            | 188 (62.05)   | 173 (67.05)        | 15 (33.33)            |           |
| >70                              | 47 (15.51)    | 19 (7.36)          | 28 (62.22)            |           |
| **Menopausal status**            |               |                    |                       | 0.002     |
| Premenopausal                    | 75 (24.75)    | 72 (27.91)         | 3 (6.67)              |           |
| Postmenopausal                   | 228 (75.25)   | 186 (72.09)        | 42 (93.33)            |           |
| **Comorbidity**                  |               |                    |                       | <0.001    |
| 0                                | 184 (60.73)   | 170 (65.89)        | 14 (31.11)            |           |
| 1                                | 81 (26.73)    | 67 (25.97)         | 14 (31.11)            |           |
| ≥2                               | 38 (12.54)    | 21 (8.14)          | 17 (37.78)            |           |
| **Histologic type**              |               |                    |                       | 0.145     |
| IDC                              | 279 (92.08)   | 240 (93.02)        | 39 (86.67)            |           |
| Non-IDC                          | 24 (7.92)     | 18 (6.98)          | 6 (13.33)             |           |
| **Tumor grade**                  |               |                    |                       | 0.004     |
| I                                | 17 (5.61)     | 11 (4.26)          | 6 (13.33)             |           |
| II                               | 205 (67.66)   | 169 (65.50)        | 36 (80.00)            |           |
| III                              | 81 (26.73)    | 78 (30.23)         | 3 (6.67)              |           |
| **Tumor size (cm)**              |               |                    |                       | 0.118     |
| ≤2                               | 156 (51.49)   | 128 (49.61)        | 28 (62.22)            |           |
| >2                               | 147 (48.51)   | 130 (50.39)        | 17 (37.78)            |           |
| **Breast surgery**               |               |                    |                       | 0.330     |
| BCS                              | 102 (33.66)   | 84 (32.56)         | 18 (40.00)            |           |
| Mastectomy                       | 201 (66.34)   | 174 (67.44)        | 27 (60.00)            |           |
| **Positive ALN(s)**              |               |                    |                       | 0.333     |
| Micro-metastasis                 | 60 (19.80)    | 48 (18.60)         | 12 (26.67)            |           |
| 1                                | 159 (52.48)   | 134 (51.94)        | 25 (55.56)            |           |
| 2                                | 68 (22.44)    | 61 (23.64)         | 7 (15.56)             |           |
| 3                                | 16 (5.28)     | 15 (5.81)          | 1 (2.22)              |           |
| **ER (%)**                       |               |                    |                       | 0.264     |
| ≥50                              | 296 (97.69)   | 251 (97.29)        | 45 (100.00)           |           |
| <50                              | 7 (2.31)      | 7 (2.71)           | 0 (0.00)              |           |
| **PR (%)**                       |               |                    |                       | 0.028     |
| ≥20                              | 222 (73.27)   | 183 (70.93)        | 39 (86.67)            |           |
| <20                              | 81 (26.73)    | 75 (29.07)         | 6 (13.33)             |           |
| **Ki-67 (%)**                    |               |                    |                       | <0.001    |
| <14                              | 114 (37.62)   | 86 (33.33)         | 28 (62.22)            |           |
| ≥14                              | 189 (62.38)   | 172 (66.67)        | 17 (37.78)            |           |
| **Molecular subtype**            |               |                    |                       | <0.001    |
| Luminal A-like                   | 79 (26.07)    | 57 (22.09)         | 22 (48.89)            |           |
| Luminal B-like                   | 224 (73.93)   | 201 (77.91)        | 23 (51.11)            |           |
| **21-gene RS**                   |               |                    |                       | <0.001    |
| Low RS                           | 59 (19.47)    | 35 (13.57)         | 24 (53.33)            |           |
| Intermediate RS                  | 178 (58.75)   | 158 (61.24)        | 20 (44.44)            |           |
| High RS                          | 66 (21.78)    | 65 (23.99)         | 1 (2.22)              |           |
When stratified by menopausal status, 3 out of 75 premenopausal patients omitted chemotherapy (Supplementary Table S3). For postmenopausal pN1 patients, elder age ($P < 0.001$), more comorbidities ($P = 0.016$), higher 21-gene RS ($P = 0.001$) were independent impact factors for chemotherapy recommendation (Table 3). Compared to low RS patients, those with intermediate RS (OR 6.36, 95% CI 2.10–19.31, $P = 0.001$) or high RS (OR 48.89, 95% CI 3.38–708.44, $P = 0.004$) were more likely to receive chemotherapy recommendation.

Change in chemotherapy recommendation before and after 21-gene RS assay. The distribution of pre- and post-RS chemotherapy recommendation was presented in Fig. 3. Overall, physician’s treatment recommendation changed for 9.57% (29/303; Table 4) patients. The most apparent alteration was found in the low RS group, with 6 (10.17%) patients changing from chemotherapy to no chemotherapy, and 2 (3.39%) patients reversely. Eighteen (10.11%) intermediate RS patients switched to receive chemotherapy, whose median was 24.5 (18.0–29.0). Two patients in the high risk group were changed to receive chemotherapy, while another patient was recommended to omit chemotherapy after MDT, since this patient was 82 years old with medical history of hypertension, type 2 diabetes, and severe cerebral infarction. Supplementary Table S5 compared the clinico-pathological features between patients with or without chemotherapy recommendation alteration. Tumor grade, tumor size, positive lymph node number, Ki-67 level and molecular subtype were significantly associated with treatment recommendation change in univariate model. Multivariate analysis showed that patients with greater tumor size (>2 cm vs ≤2 cm, OR 0.36, 95% CI 0.15–0.89, $P = 0.026$; Supplementary Table S6) or 2 positive lymph nodes (2 vs micro-metastasis, OR 0.07, 95% CI 0.01–0.58, $P = 0.014$) were less likely undergo treatment recommendation change.

Table 5 showed the chemotherapy regimen recommended before and after 21-gene RS result. In the low RS group, TC*4 was the most frequently recommended regimen both before (47.46%) and after (40.68%) RS assay testing. For patients with intermediate risk, EC-T was suggested in 33.15% and 33.15% patients pre- and post-assay, respectively. Recommendation of TC*4 increased from 36.52% to 47.19% after receiving RS result. Moreover, in the high risk group, EC-T was proposed to 57.58% before and 63.64% after having 21-gene RS results.

Actual adjuvant chemotherapy usage and disease outcomes. With respect to the actual adjuvant chemotherapy usage, 16 patients didn’t follow the treatment recommendation (Table 4), with adherence rate with MDT decision 94.72% (287/303) in the whole population. Regarding patients with different RS, the adherence...
rate with MDT decision about adjuvant chemotherapy was 98.31% (58/59), 92.70% (165/178), and 96.97% (64/66) in the low RS, intermediate RS, and high RS groups, respectively ($P = 0.162$).

After a median follow-up of 21.17 (range 1.38 to 55.43) months, 11 (3.63%) DFS events were observed, including 4 local regional recurrences, 5 distant metastases, 1 second primary malignancy, and 1 death. The detailed information of the 11 patients with DFS events were summarized in Supplementary Table S4. There was no significant DFS difference among different risk groups ($P = 0.225$).

Discussion

In this study, we included 303 HR$^+$/HER2- and pN1 BC patients with 21-gene RS records. The distribution of RS was 19.47%, 58.75%, and 21.78% for low, intermediate, and high risk group, respectively. Chemotherapy was recommended for 258 patients after MDT meeting. We found that age, comorbidity, and 21-gene RS were independently associated with chemotherapy recommendation in the whole population and for postmenopausal patients. Treatment recommendation changed for 9.57% patients after RS results. The overall adherence rate of actual chemotherapy usage to MDT decision was 94.72% (287/303). To our knowledge, this is the first and largest study in Chinese population to focus on 21-gene RS and adjuvant chemotherapy decision in ALN$^+$ BC patients.

Earlier data from our center revealed that among node-negative and node-positive BC population receiving 21-gene RS tests, 26.1%, 49.3% and 24.6% were categorized into low, intermediate and high RS groups, respectively$^{19}$. Tumor grade, PR status, and Ki-67 were significantly associated with RS category in the whole population$^{19}$, which was consistent with evidence from other centers$^{20,21}$. In this current study, grade, ER status, and PR status were identified as independent factors associated with RS in pN1 patients.

We found that the RS category was independently associated with chemotherapy recommendation in pN1 patients in our study, which was in consistency with previous findings$^{22,24}$. For low RS pN1 patients, 40.68% (24/59) were exempt from chemotherapy. Based on Surveillance, Epidemiology, and End Results (SEER) database, Roberts et al. concluded that the 5-year breast cancer specific survival (BCSS) was 98.9%, 99.4%, 97.1% and, 95.1% for those RS < 18 with micro-metastases, 1, 2 and, 3 positive ALN(s), respectively$^{25}$. Similarly, in the WGS Plan B trial, the 5-year DFS in RS < 11 N$^+$ patients treated with endocrine therapy alone was 94% after a median follow-up of 55 months$^{12,13}$. Nevertheless, given the relatively short follow-up for ER-positive disease, and an increase in DFS events of 5.6% at 5-year compared with the 3-year results, we cannot spare all RS < 11 N$^+$ patients from chemotherapy. The optimal cutoff in node-positive patients remains unclear. Actually,

| Characteristics | Odds ratio | 95% Confidence interval | $P$-value |
|-----------------|------------|-------------------------|----------|
| Age (years)     |            |                         |          |
| $<$50           | 1.0        |                         |          |
| 50–70           | 0.20       | 0.01–3.47               | 0.271    |
| $>$70           | 0.01       | 0.00–0.11               | 0.001    |
| Menopausal status |          |                         |          |
| Premenopausal   | 1.0        |                         |          |
| Postmenopausal  | 1.79       | 0.14–22.72              |          |
| Comorbidity     |            |                         |          |
| 0               | 1.0        |                         |          |
| 1               | 1.14       | 0.37–3.51               | 0.826    |
| $\geq$2         | 0.08       | 0.02–0.46               | 0.004    |
| Tumor grade     |            |                         |          |
| I               | 1.0        |                         |          |
| II              | 2.37       | 0.54–10.47              | 0.254    |
| III             | 6.72       | 0.76–59.37              | 0.086    |
| PR              |            |                         |          |
| <20             | 1.0        |                         |          |
| $\geq$20        | 1.15       | 0.23–5.66               |          |
| Ki-67 (%)       |            |                         |          |
| <14             | 1.0        |                         |          |
| $\geq$14        | 1.03       | 0.17–6.13               |          |
| Molecular subtype |          |                         |          |
| Luminal A-like  | 1.0        |                         |          |
| Luminal B-like  | 3.88       | 0.60–25.19              |          |
| 21-gene RS      |            |                         |          |
| Low RS          | 1.0        |                         |          |
| Intermediate RS | 6.58       | 2.37–18.31              |          |
| High RS         | 54.14      | 3.77–776.54             |          |

Table 2. Multivariate analysis of impact factors for chemotherapy recommendation. Abbreviations: RS, recurrence score.
the two classification (classic classification of 18–30, the new TAILORx classification of 11–25) are both in use in clinical practice. Based on previous evidence, the 18–30 is more frequently adopted when doing prognostic analysis (for example in transATAC trial), while the 11–25 is more frequently applied when studying the predictive value. We carried out a Chi-square test to compare two different classifications, and the Chi-square value is 22.6 when applying the new classification, compared to 42.2 when applying the classic classification. In addition, we found that the chemotherapy recommendation rates were similar between patients with RS < 11, and RS 11–17 (65.00% vs 56.41%, P = 0.525, Fig. 2B), but much lower than those with RS ≥ 18 (P < 0.001). As a result, we adopted the cutoff of 18–30 in the current study. The ongoing prospective randomized phase III RxPONDER trial is designed to study the efficacy of adjuvant endocrine therapy with or without chemotherapy in HR-positive, HER2-negative patients with 1–3 positive ALNs, RS ≤ 25. The results are awaited to evaluate the interaction of RS and chemotherapy benefit in pN1 patients, and to estimate a clinical meaningful cutoff point for chemotherapy recommendation in this subgroup26.

The influence of 21-gene RS on chemotherapy usage has been noticed. According to data from other centers, the change in adjuvant treatment recommendations for node-positive patients after 21-gene RS assay was 21%–39%, in the direction of exempting from chemotherapy23,27–30. Meanwhile, our data showed that only 9.57%...
patients received inconsistent adjuvant treatment recommendation before and after 21-gene RS assay, and more patients of intermediate risk group were recommended with chemotherapy after RS results. One possible reason was that, in previous studies of other centers, chemotherapy recommendation both pre- and post-21-gene RS assay were made by individual clinician or only one-round MDT, which might be more frequently influenced by RS results. In our clinical practice, however, chemotherapy recommendation pre- and post-21-gene RS assay were both made through two-round MDT meetings. Our previous study about MDT found that MDT changed the traditional single-disciplinary treatment mode, and showed significant advantages in providing better treatment options for patients31. Such effect of MDT decision might thus dilute the impact of 21-gene RS on chemotherapy recommendation.

| Post-21-gene RS | Chemo | Non-chemo | Pre-RS to Post-21-gene RS change (%) | Actual application | Actual use adherence to post-21-gene RS testing (%) |
|----------------|-------|-----------|-------------------------------------|-------------------|-----------------------------------------------|
|                |       |           |                                     |                   |                                               |
| Whole population |      |           |                                     |                   |                                               |
| Chemo          | 236   | 22        | 29/303 (9.57%)                      | 245 13            | 287/303 (94.72%)                              |
| Non-chemo      | 7     | 38        |                                     | 3 42              | 94.72%                                        |
| Low RS (RS < 18) |      |           |                                     |                   |                                               |
| Chemo          | 33    | 2         | 8/59 (13.56%)                       | 35 0              | 58/59 (98.31%)                                |
| Non-chemo      | 6     | 18        |                                     | 1 23              |                                               |
| Intermediate RS (RS 18–30) | |           |                                     |                   |                                               |
| Chemo          | 140   | 18        | 18/178 (10.11%)                     | 147 11            | 165/178 (92.70%)                              |
| Non-chemo      | 0     | 20        |                                     | 2 18              |                                               |
| High RS (RS ≥ 31) |      |           |                                     |                   |                                               |
| Chemo          | 63    | 2         | 3/66 (4.55%)                        | 63 2              | 64/66 (96.97%)                                |
| Non-chemo      | 1     | 0         |                                     | 0 1              |                                               |

Table 4. Chemotherapy recommendation before, after 21-gene RS assay and actual use. Abbreviations: Chemo, chemotherapy; RS, recurrence score.

| 21-gene RS | Regimen | Recommendation before 21-gene RS, N (%) | Recommendation after 21-gene RS, N (%) | Therapy actually achieved, N (%) |
|------------|---------|----------------------------------------|----------------------------------------|---------------------------------|
| Whole population | | | | |
| EC-T | 104 (34.32) | 104 (34.32) | 93 (30.69) |
| TC*4 | 113 (37.29) | 122 (40.26) | 118 (38.94) |
| TC*6 | 24 (7.92) | 27 (8.91) | 25 (8.25) |
| Other | 2 (0.66) | 5 (1.65) | 12 (3.96) |
| None | 60 (19.80) | 45 (14.85) | 55 (18.15) |

| RS < 18 N = 59 | | | |
| EC-T | 7 (11.86) | 3 (5.08) | 2 (3.39) |
| TC*4 | 28 (47.46) | 24 (40.68) | 26 (44.07) |
| TC*6 | 3 (5.08) | 6 (10.17) | 6 (10.17) |
| Other | 1 (1.69) | 2 (3.39) | 2 (3.39) |
| None | 20 (33.90) | 24 (40.68) | 23 (38.98) |

| RS 18–30 N = 178 | | | |
| EC-T | 59 (33.15) | 59 (33.15) | 55 (30.90) |
| TC*4 | 65 (36.52) | 84 (47.19) | 79 (44.38) |
| TC*6 | 16 (8.99) | 13 (7.30) | 10 (5.62) |
| Other | 0 (0.00) | 2 (1.12) | 5 (2.81) |
| None | 38 (21.35) | 20 (11.24) | 29 (16.29) |

| RS ≥ 31 N = 66 | | | |
| EC-T | 38 (57.58) | 42 (63.64) | 36 (54.55) |
| TC*4 | 20 (30.30) | 14 (21.21) | 13 (19.70) |
| TC*6 | 5 (7.58) | 8 (12.12) | 9 (13.64) |
| Other | 1 (1.52) | 1 (1.52) | 5 (7.58) |
| None | 2 (3.03) | 1 (1.52) | 3 (4.55) |

Table 5. Chemotherapy regimen recommendation before and after 21-gene RS assay. Abbreviations: EC-T, 4 cycles of epirubicin and cyclophosphamide every 21 days followed by 4 cycles of docetaxel every 21 days or 12 cycles of weekly paclitaxel; RS, recurrence score; TC*4, 4 cycles of docetaxel plus cyclophosphamide every 21 days; TC*6, 6 cycles of docetaxel plus cyclophosphamide every 21 days.
Previous studies have indicated that 21-gene RS assay provides additional prognostic information beyond clinico-pathological features. For example, Wang et al. analyzed data of 4059 T1–N1–M0 patients with ER-positive, HER2-negative diseases with available 21-gene RS results from the SEER database. Their study indicated that the RS risk categories were positively associated with pathological prognostic stages \((P < 0.001)\) based on the 8th edition of American Joint Commission on Cancer (AJCC). The RS risk category was an independent prognostic factor for BCSS and overall survival\(^5\). Similarly, another SEER database-based study found that RS result was a strong predictor of BCSS for patients with micro-metastases or 1–3 positive ALNs \((P < 0.001)\)\(^9\). In addition, other retrospective studies demonstrated that RS result was an independent impact factor for local regional recurrence \((\text{Hazard ratio} = 2.59, 95\% \text{CI 1.28–5.26, } P = 0.008)\)\(^29\) and distant recurrence \((\text{Hazard ratio} = 3.47, 95\% \text{CI 1.64–7.38, } P = 0.002)\)\(^23\) in ER-positive, node-positive patients. Our study found that after a median follow-up of 21.17 months, 11 (3.63%) DFS events were observed in these node-positive patients. Due to the relative short period of follow-up and small number of DFS events, we cannot assess the prognostic value of 21-gene RS in ALN positive BC patients, which warranted further evaluation.

Several limitations existed in the current study. To begin with, 245 (44.38%) pN1 patients didn’t receive a 21-gene RS test since not enough data supported the application of 21-gene RS in node-positive patients at time of diagnosis, which might introduce bias. Secondly, the RS distribution differed from previous data from other clinical trials like SWOG S8814 and transATAC. This might be explained by the difference in clinico-pathological features between the enrolled cohorts. For example, in the SWOG8814 trial, 35.7%, 52.9% and 11.4% patients had grade 1,2 and 3 tumor, compared to 5.6%, 67.7% and 26.7% in our cohort. Moreover, given that there was limited evidence about the application of 21-gene RS in node-positive patients, we recommended 21-gene RS testing for N+ patients increasingly but not routinely, only after the publication of SWOG S8814 and WGS Plan B trials, thus the follow-up was too short to clarify the prognostic effect of 21-gene RS, which needed continuous follow-up.

Conclusions

In conclusion, 21-gene RS category independently influenced chemotherapy recommendation in HR+/HER2- BC patients with 1–3 positive ALNs. Chemotherapy recommendation changed for 9.57% patients after 21-gene RS results, which provide relatively little information to guide adjuvant treatment decision in these patients before the publication of RxPONDER trial. After 21-gene RS testing, ALN positive patients had a good adherence to MDT decision. Further analysis is warranted to clarify the prognostic and chemotherapy predictive value of 21-gene RS in pN1 breast cancer patients.

Data Availability

The datasets analysed during the current study are available from the corresponding authors on reasonable request.

References

1. Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018).
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 379(9814), 432–444 (2012).
3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 393(10179), 1440–1452 (2019).
4. Delduluri, N. et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 36(23), 2433–2443 (2018).
5. Sparano, J. A. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 373(21), 2005–2014 (2015).
6. Paik, S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 12(6), 631–635 (2007).
7. Sparano, J. A. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 379(2), 111–121 (2018).
8. Gradishar, W. et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2018. Accessed February 8. To view the most recent version of these guidelines, visit NCCN.org (2019).
9. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24(23), 3726–3734 (2006).
10. Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11(11), 55–65 (2010).
11. Goldstein, L. J. et al. Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicoopathologic Features. Journal of Clinical Oncology. 26(25), 4063–4071 (2008).
12. Gluz, O. et al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol. 34(20), 2341–2349 (2016).
13. Nitz, U. et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk, pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WGS) PlanB trial. Breast Cancer Res Treat. 165(3), 573–583 (2017).
14. Chen, X. et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer. 13, 390 (2013).
15. Tong, Y. et al. Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease? Eur J Cancer. 89, 9–18 (2018).
16. Goldhirsh, A. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20(8), 1319–1329 (2009).
17. Wolff, A. C. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 36(20), 2105–2122 (2018).
18. Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24(9), 2206–2223 (2013).
19. Wu, J. et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget. 8(24), 38706–38716. (2017).
20. Clark, B. Z. et al. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases. Appl Immunohistochem Mol Morphol. 21(4), 287–91. (2013).
21. Ozmen, V. I. et al. Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey. J Breast Health. 12(3), 107–111 (2016).
22. Jasem, J. et al. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? Journal of the National Comprehensive Cancer Network: JNCCN. 15(4), 494–503 (2017).
23. Torres, S. et al. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. The Oncologist. 23(7), 768–775 (2018).
24. Jones, H. et al. Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer. Contemp Clin Trials. 63, 30–39 (2017).
25. Roberts, M. C. et al. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Research and Treatment. 163(2), 303–310 (2017).
26. SWOG RxPONDER Trial (S1007): Patient Information. Available at, http://swog.org/Visitors/S1007/patients.asp, Accessed February 20, 2017.
27. Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 28(11), 1829–1834 (2010).
28. Eiermann, W. et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Annals of Oncology. 24(3), 618–624 (2012).
29. Fried, G. & Moskowitz, M. Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results. Springerplus. 3, 71 (2014).
30. Kurian, A. W. et al. Recent Trends in Chemotherapy Use and Oncologists’ Treatment Recommendations for Early-Stage Breast Cancer. JCN. 110(5), 493–500 (2018).
31. Hong, J. et al. Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer. Zhonghua Zhong Liu Za Zhi. 39(1), 39–43 (2017).
32. Wang, M. et al. The Prognostic Significance of the Oncotype DX Recurrence Score in T1-2N1M0 Estrogen Receptor-Positive HER2-Negative Breast Cancer Based on the Prognostic Stage in the Updated AJCC 8th Edition. Ann Surg Oncol. 2018.
33. Mamounas, E. P. et al. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. Journal of the National Cancer Institute. 109(4), djw259 (2017).

Acknowledgements
The authors would like to thank Ms. Yidong Du for her assistance in the operation and management of SJTU-BCDB, and Dr. Yitian Xiao from University of California, Davis for language polishing. The authors appreciated the financial support from the National Natural Science Foundation of China (Grant Number: 81772797), Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support (20172007); Ruijin Hospital, Shanghai Jiao Tong University School of Medicine—“Guangci Excellent Youth Training Program” (GCQN-2017-A18). All these financial sponsors had no role in the study design, data collection, analysis or interpretation.

Author Contributions
Y.T. analyzed and interpreted the patient data and was a major contributor in writing the manuscript; J.W., O.H., J.H., L.Z., W.C. and Y.L. contributed to the data collection and acquisition; X.C. made substantial contributions to the conception of the work; K.S. substantively revised the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-49644-6.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019